Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Patritumab (Process 2) plus erlotinib in advanced NSCLC
jRCT2080222789Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, single-arm trial of patritumab in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.
02
Drugs
patritumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222789.